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Splice variants as novel targets in 
pancreatic ductal adenocarcinoma
Jun Wang1, Laurent Dumartin1, Andrea Mafficini  2, Pinar Ulug  1, Ajanthah 
Sangaralingam1, Namaa Audi Alamiry1, Tomasz P. Radon1, Roberto Salvia2, Rita T. Lawlor2, 
Nicholas R. Lemoine1, Aldo Scarpa  2, Claude Chelala1 & Tatjana Crnogorac-Jurcevic1
Despite a wealth of genomic information, a comprehensive alternative splicing (AS) analysis of 
pancreatic ductal adenocarcinoma (PDAC) has not been performed yet. In the present study, we 
assessed whole exome-based transcriptome and AS profiles of 43 pancreas tissues using Affymetrix 
exon array. The AS analysis of PDAC indicated on average two AS probe-sets (ranging from 1–28) 
in 1,354 significantly identified protein-coding genes, with skipped exon and alternative first exon 
being the most frequently utilised. In addition to overrepresented extracellular matrix (ECM)-
receptor interaction and focal adhesion that were also seen in transcriptome differential expression 
(DE) analysis, Fc gamma receptor-mediated phagocytosis and axon guidance AS genes were also 
highly represented. Of note, the highest numbers of AS probe-sets were found in collagen genes, 
which encode the characteristically abundant stroma seen in PDAC. We also describe a set of 37 
‘hypersensitive’ genes which were frequently targeted by somatic mutations, copy number alterations, 
DE and AS, indicating their propensity for multidimensional regulation. We provide the most 
comprehensive overview of the AS landscape in PDAC with underlying changes in the spliceosomal 
machinery. We also collate a set of AS and DE genes encoding cell surface proteins, which present 
promising diagnostic and therapeutic targets in PDAC.
Alternative splicing (AS) is one of the key regulatory events leading to transcriptome and proteome diversity. 
From bacteria and archaea, AS has, through increased prevalence, contributed to driving speciation and shaped 
the evolution of all multicellular organisms, including our own species1. Multiple distinct transcript variants are 
encoded by the majority, if not all human multi-exon genes, and more than half of all AS events show tissue spec-
ificity, thus highlighting a critical role of AS in creating phenotypic complexity2–4.
The functional consequences of most AS events are still unknown, with some resulting in non-functional 
products, some in the splice variant product(s) that assume completely different function from the wild-type pro-
tein, and in some cases the proteins even acquire antagonistic functions (for review see ref. 5). It is not surprising 
then that cancer has harnessed this important regulatory mechanism, which is implicated in all the ‘hallmark’ 
pathways of cancer6, and can hence be considered an additional cancer hallmark itself7. Some of the spliced var-
iants in pre-malignant lesions have also been found in advanced cancers, suggesting their potential as drivers of 
cancer development and progression8.
Distinct patterns of cancer-specific splicing when compared to normal tissue counterparts have been reported 
for a variety of tumours9, 10, some of which could play a role as promising diagnostic, prognostic and/or therapeu-
tic targets5. In pancreatic ductal adenocarcinoma (PDAC), in contrast to a wealth of other genomic data, except 
for a cell line study11, no AS data on a whole genome scale have yet been reported. A detailed understanding of 
the alternative splicing landscape in PDAC is therefore warranted; with this in mind, we have undertaken an 
in-depth investigation of AS events combined with whole transcriptome analysis, and explored the alterations in 
the splicing machinery itself in normal and pancreatic cancer specimens.
Results
Exon-based whole transcriptome profiling in PDAC. We used Affymetrix exon array to generate 
whole exome-based profiles for 28 PDAC (Table 1) and six normal pancreas bulk tissues. Although widely used as 
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a normal comparator, we are aware that this can be a potential source of bias when comparing non-ductal acinar 
tissue versus ductal-differentiated carcinoma.
Firstly, we analysed the expression profiles for 225,925 probe-sets across all exons and 17,528 transcript clus-
ters after intensity filtering for all samples (see Methods). Unsupervised hierarchical clustering demonstrated a 
clear separation of the control and PDAC sample groups based on both probe-set and transcript level expression 
(Supplementary Fig. S1). In total, 1,887 transcript clusters were differentially expressed (DE) in PDAC com-
pared to normal pancreas, of which 1071 (56.8%) were upregulated and 816 (43.2%) downregulated. Among 
these, 1,600 corresponded to protein-coding genes, with 917 (57.3%) upregulated and 683 (42.7%) downregu-
lated transcript clusters in PDAC (Fig. 1A, Supplementary Table S1A). The KEGG pathway enrichment test using 
DAVID12 suggested that the identified overexpressed genes in PDAC were highly enriched for extracellular matrix 
(ECM)-receptor interaction (adj. p = 1.22e-05) and focal adhesion (adj. p = 2.37e-05), while for downregulated 
genes in PDAC, glycine, serine and threonine metabolism (adj. p = 9.40e-05) and maturity onset diabetes of the 
young (adj. p = 8.75e-05) were highly overrepresented (Fig. 1B, Supplementary Table S1B). The top deregulated 
canonical pathways based on Ingenuity pathways analysis (IPA) included small GTPases (CDC42, Rho), integrin 
and actin cytoskeleton signalling, again pointing to ECM-interaction, adhesion and cytoskeletal regulation. A 
full list of the pathways with the corresponding key genes is provided in Supplementary Table S1C. Analysis of 
the obtained differential expression profiles using the Pancreatic Expression Database13 revealed that out of 917 
PDAC case number Gender Age Grade pT pN pM Analysis
13 F 73 G2 T3 N1 M0 EA
14 M 64 G2 T3 N1 M0 EA
16 F 50 G2 T3 N1 M0 EA/qPCR
17 F 59 G3 T3 N1 M0 EA/qPCR
19 M 62 G2 T3 N1 M0 EA/qPCR
20* M 63 G3 T3 N1 M0 EA
21 F 77 G2 T3 N1 M0 EA
22 M 80 G2 T3 N1 M0 EA/qPCR
23 M 73 G2 T3 N1 M0 EA/qPCR
24 F 59 G3 T3 N1 M0 EA/qPCR
25 F 71 G2 T3 N1 M0 EA
27 F 42 G2 T2 N1 M0 EA/qPCR
32 M 67 G2 T3 N1 M0 EA/qPCR
35 F 68 G2 T4 N0 M0 EA
46 M 68 G2 T1 N0 M1 EA/qPCR
54 F 41 G3 T2 N0 M0 EA/qPCR
55 M 55 G2 T3 N1 M0 EA
60 F 65 G3 T3 N1 M0 EA/qPCR
63 M 67 G3 T4 N1 M0 EA/qPCR
64 M 59 G3 T3 N1 M0 EA
80 M 74 G2 T3 N1 M0 EA
100 F 73 G2 T3 N0 M0 EA/qPCR
102 F 73 G2 T3 N1 M0 EA
108 M 59 G3 T4 N1 M0 EA
150 M 53 G3 T3 N1 M0 EA
163 M 64 G2 T3 N1 M0 EA
169 M 66 G2 T4 N1 M0 EA
173 M 60 G3 T3 N1 M0 EA
89 M 81 G2 T4 N1 M0 qPCR
71 F 67 G3 T3 N1 M0 qPCR
73 F 74 G2 T3 N1 M0 qPCR
75 F 32 G2 T3 N0 M0 qPCR
95 M 68 G3 T3 N1 M0 qPCR
152 M 62 G3 T3 N0 M0 qPCR
166 F 65 G2 T3 N1 M0 qPCR
11 F 59 G3 T3 N1 M0 qPCR
15 F 67 G3 T3 N1 M0 qPCR
Table 1. Demographic and clinical information of the analysed PDAC samples. *This sample was derived 
from the patient that received neoadjuvant therapy (Gemcitabine + Oxaliplatin; all the remaining samples 
were obtained from naive patients. EA = exon array; qPCR = quantitative polymerase chain reaction; pTNM 
(pathology staging: Tumour, lymph Nodes, Metastasis).
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upregulated and 683 downregulated protein-coding genes in PDAC, 657 (71%) and 219 (32%) were previously 
reported displaying the same directions of changes, respectively (Supplementary Table S1D). Among the newly 
discovered deregulated genes (701/1600; 44%), IPA revealed ephrin receptor and G-protein regulatory Gαi sig-
nalling as top deregulated canonical pathways (Supplementary Table S1E). Therefore, our exon-based expression 
analysis, with over four-fold increase in probe density in comparison to the ‘classical’ 3′-based arrays, provided a 
far more accurate and comprehensive portrait of pancreatic cancer transcriptome.
Interestingly, the transcriptomic profile of the 28 analysed PDAC samples also indicated the existence of two 
PDAC subgroups (Fig. 1A). This has prompted us to interpret our analysis in light of the previously reported 
PDAC subclassification by Collisson et al.14; the three PDAC groups: exocrine-like (n = 10), classical (n = 10) 
and QM-PDA (n = 8) are shown on Fig. 1C. The 11 closely grouped PDAC samples based on all 1,887 DE tran-
script clusters as indicated by the orange block in Fig. 1A were highly enriched for exocrine-like samples (n = 8, 
73%). This group showed a higher level of expression of 255 transcripts compared to the rest of the PDAC sam-
ples, including pancreatic lipase-related protein PNLIPRP2 and chymotrypsin-like elastase family, member 2B 
(CELA2B) genes, classical acinar-originating genes (Supplementary Table S1F). KEGG pathway analysis fur-
ther showed, in contrast to the other, ‘non-exocrine’ PDAC subgroup, that this cluster of genes was also highly 
enriched for glycine, serine and threonine metabolism, glutathione metabolism and selenoamino acid metabo-
lism as well as Maturity onset diabetes of the young (Supplementary Table S1F), pointing to potential underlying 
metabolic and functional differences between the two subgroups. However, no difference in survival between 
exocrine-like enriched and ‘non-exocrine’ patients’ groups was seen (log rank P = 0.822). Furthermore, no sig-
nificant difference in survival was present between any of the three Collisson subgroups shown in Fig. 1C (log 
rank P = 0.277).
Figure 1. Differentially expressed protein-coding genes in PDAC. (A) Heatmap of the 1,887 differentially 
expressed transcript clusters in PDAC. The heatmap represents relative over- (red) and under-expressed (green) 
genes. The covariates at the top represent tumour (red) and normal (blue) samples. A subgroup of 11 PDAC 
samples is indicated by the orange box, determined by the exocrine-like gene signature by Collisson et al. with 
higher expression in a cluster of 255 transcripts than other PDAC samples. (B) KEGG pathway enrichment 
test for significantly up- and down-regulated genes in PDAC. The BH adjusted p-values were used (x-axis). 
(C) Heatmap and sample clustering based on the Collisson signature dividing samples into three molecular 
subtypes.
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After integration of our data with the data from Zhang et al. (n = 70 in the merged dataset)15 (Supplementary 
Fig. S2), no significant association of any of the three PDAC subgroups with survival was identified. This is in 
agreement with the study by Moffitt et al.16, where the sample grouping was determined by the histology (as 
similarly confirmed recently by Bailey et al.17) with the presence of the stable exocrine-like signature in PDAC 
reflecting the remnant exocrine-like compartment in the samples. Therefore, our results are not inconsistent with 
the cited studies16, 17, and have to be interpreted in light of the interrogated material, which in large part ( > 60%) 
comprised the malignant cell component.
Alternative splicing landscape in pancreatic cancer. After transcriptome analysis, we have undertaken 
a detailed AS analysis: in total, 2,816 differentially spliced probe-sets, representing 1,354 protein-coding genes, 
were identified (Supplementary Table S2A). This corresponded to on average 2.08 AS probe-sets per gene, rang-
ing from 1–28. Of note, around half (1,424/2816; 50.5%) of these splicing events have not been reported previ-
ously in the Ensembl alternative splicing event set. The major AS event types found are listed in Table 2. Cassette 
exon (skipped exon, 14.3%) and alternative first exon (14.0%) were the most frequent, followed by intron reten-
tion (8.4%). Hierarchical clustering based on the FIRMA scores clearly separated the PDAC and control groups 
(Fig. 2A), suggesting a strong PDAC-specificity of the obtained splicing pattern. Interestingly, two subgroups of 
PDAC specimens were clearly evident. Since AS is shown to be associated with subtypes of breast cancer18, we 
explored this further, but subgrouping did not appear to correspond either to the one generated by DE signatures 
(Fig. 1A), nor any of the three Collisson sub-groups, and no difference in survival between the two groups was 
seen (log rank P = 0.433). We also did not find any association between tumour cellularity and tumour sample 
grouping based on DE or AS signatures. In addition, no association was observed between the tumour grade and 
these groups. However, it still remains to be explored if any other clinical correlates would emerge from these two 
AS subgroups in other studies.
Among differentially spliced probe-sets, 949 (33.7%) representing 555 genes were included in PDAC samples, 
while the remaining 66% (1,867 probe-sets/1,155 genes) were skipped in PDAC compared to normal samples 
(Supplementary Table S2A). Among 1,354 protein-coding genes with AS signatures, around half (638, 47%) had 
more than one alternatively spliced probe-set, while genes from the collagen family had the highest number of 
AS probe-sets, including 28 for COL5A1, 19 for COL11A1, 17 for COL5A2, 12 for COL16A1 and 11 for COL1A1 
and COL17A1 (Supplementary Table S2B). For example, AS events of COL1A1 indicated by the 11 significant 
probe-sets in PDAC included skipped first exon (n = 1 probe-set) and highly included last exon/3′ UTR (n = 4), 
as well as cassette exons in the gene body (Supplementary Fig. S3A). These are significant findings, considering 
the abundance and increasingly recognised role of the stromal environment in PDAC.
In general, there was a weak positive correlation between the number of AS probe-sets and the number of total 
core probe-sets (Spearman’s rank correlation r = 0.26) and the number of exons (Spearman’s correlation r = 0.16), 
as noted previously for AS genes3, suggesting that selection pressure may play a role in limiting the splicing com-
plexity in exceptionally large genes in PDAC as well.
The top ten most differentially spliced probe-sets (both skipped and included) are shown in Table 3.
To understand the putative roles of AS in PDAC, we performed detailed pathway analyses using both DAVID 
KEGG pathway and IPA enrichment tests. Interestingly, the KEGG pathway enrichment test suggested that AS 
genes were, similarly to DE genes, highly enriched for ECM-receptor interaction and focal adhesion (Fig. 2B; 
Supplementary Table S2C), highlighting again the importance of cancer cell-stroma interaction as a key biolog-
ical feature of pancreatic cancer. In addition, Fc gamma R-mediated phagocytosis (adj. p = 2.49e-03) and axon 
guidance (adj. p = 2.81e-03) were also significantly overrepresented for genes with skipped probe-sets. Within 
the axon guidance pathway, the importance of which was recently flagged19, 26 genes (60 probe-sets) displayed 
significant AS signatures (Fig. 2C). While 10 of these genes (ABLIM3, EFNA5, EPHB4, ITGB1, RAC2, RGS3, 
ROBO1, ROCK2, SEMA7A and UNC5B) had both included and skipped probe-sets in PDAC, the majority (65%) 
of 60 AS probe-sets were skipped in PDAC (Fig. 2C; Supplementary Table S2D). For ITGB1, events of alternative 
(skipped) first exon, included and skipped exons and potential included last exon were identified. It is likely the 
short isoform was the preferred transcript in PDAC (Supplementary Fig. S3B). The top AS signalling pathways in 
the Ingenuity pathway enrichment analysis also included integrin and axonal guidance signalling; a full list of the 
IPA pathways and key genes is provided in Supplementary Table S2E.
Splicing type Number Percentage (%)
Alternative 5′ sites (A5SS) 47 1.53
Alternative 3′ sites (A3SS) 43 1.67
Alternative first exon (AFE) 394 13.99
Alternative last exon (ALE) 33 1.17
Cassette exon (Skipped exon, CE) 402 14.28
Constitutive exon (CNE) 208 7.39
Intron retention (IR) 237 8.42
Intron isoform (II) 20 0.71
Mutually exclusive exons (MXE) 9 0.32
Table 2. Alternative splicing event types in PDAC. CE: an exon may be spliced out of the primary transcript 
or retained; CNE: constitutively spliced exons. All events were based on the nomenclature described in Wang 
et al.4.
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Among the 1,354 genes with AS signatures, 369 (27.3%) were genes coding for surface proteins 
(Supplementary Table S2F); not surprisingly, these genes appeared to be highly enriched for cell adhesion (adj. 
p = 1.10e-22), cell surface receptor-linked signal transduction (adj. p = 1.60e-09), ECM-receptor interaction (adj. 
p = 3.7E-09), positive regulation of cell activation and proliferation (adj. p = 6.71e-07 and 9.42e-07, respectively), 
and the integrin-mediated signalling pathway (adj. p = 3.10e-06), comprising a number of integrins (ITGA11, 
ITGA3, ITGA4, ITGA5, ITGAV, ITGB1, ITGB2, ITGB4 and ITGB7 (Supplementary Table S2G).
Real-time PCR validation of alternative splicing. Real-time PCR was performed using 20 PDAC and 
six normal pancreas tissues for eight splicing events from randomly selected non-differentially expressed genes 
(fold change between 0.9–1.1): C1QTNF5, SLC17A9, NR1I2, C6orf106, ABI3, OTUD5, MDFIC and DCAKD 
(Fig. 3A). As presented in Fig. 3B, the PCR results validated the exon array data with significantly higher levels 
for the included exons (C1QTNF5, SLC17A9, NR1I2, ABI3, OTUD5, MDFIC) and significantly lower levels for 
the two skipped exons (C6orf106 and DCAKD) in PDAC samples compared to normal pancreas. Thus, these data 
validated the accuracy of FIRMA prediction for exon skip/inclusion.
Identification of cell surface DE and AS regulated genes as candidate biomarkers and ther-
apeutic targets. We next established which genes were commonly regulated by both differential expres-
sion (DE) and AS, by comparing the 1,354 AS to the 1,600 DE protein-coding genes (Fig. 4, Supplementary 
Table S3A). 360 genes showed both DE and AS signatures in PDAC, accounting for 22.5% and 26.6% of total 
DE and AS genes, respectively (Fig. 4A). Upon assessing the pathways that these 360 genes modulate, we found 
a significant enrichment for ECM-receptor interaction (adj. p = 9.78e-11) and focal adhesion (adj. p = 9.05e-
06), while immunity-related pathways (particularly T cell receptor signalling (adj. p = 9.29e-04), Fc gamma 
receptor-mediated phagocytosis (adj. p = 1.12e-02), chemokine signalling, as well as neurotrophin signalling 
(which supports survival, development and function of neurons) (all with adj. p < 0.05) were predominantly 
affected by AS (Fig. 4B, Supplementary Table S3B). Actin cytoskeleton and axon guidance genes appeared to be 
regulated by both DE and AS, as well as unique AS events. This was also largely supported by IPA (Supplementary 
Table S3C).
Figure 2. Alternative splicing in PDAC. (A) Heatmap of the 2,816 alternatively spliced probe-sets based on 
the FIRMA scores, with the relative inclusion shown in red and skipping shown in green. (B) KEGG pathway 
enrichment test for genes with included and skipped events. (C) Heatmap of 60 alternatively spliced probe-sets, 
representing 26 genes involved in axon guidance (KEGG). The row names are shown in the format of “probe-
set” then followed by “gene symbol”.
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AS and DE events that affect cell surface proteins might represent an exciting opportunity for their use as 
biomarkers for detection and/or as therapeutic targets. A total of 135 cell surface protein-coding genes that are 
regulated at both gene expression and alternative splicing level are listed in Supplementary Table S3D.
The splicing pattern of two genes encoding the cell surface proteins, ROBO1 (an axon guidance gene) and 
LRP8 (Low Density Lipoprotein Receptor-Related Protein 8, which plays a critical role in the migration of neu-
rons during development), were assessed by real-time PCR (Fig. 5). ROBO1 and LRP8 displayed multiple splicing 
events according to FIRMA prediction (Supplementary Fig. S4) and were upregulated in PDAC compared to 
Probe-
set_ID
Transcript 
cluster_ID Symbol Definition
logFC 
(FIRMA) Event adj. P-Value
3824875 3824874 IFI30 Interferon, gamma-inducible protein 30 −11.93 skipped 6.42E-09
3861578 3861557 LGALS4 Lectin, galactoside-binding, soluble, 4 −10.80 skipped 2.66E-08
2829950 2829947 TGFBI Transforming growth factor, beta-induced, 68kDa −10.23 skipped 4.89E-09
2880347 2880292 DPYSL3 Dihydropyrimidinase-like 3 −9.75 skipped 5.24E-14
3632030 3631964 PKM2 Pyruvate kinase, muscle −9.71 skipped 9.00E-11
3119348 3119339 LY6E Lymphocyte antigen 6 complex, locus E -9.57 skipped 4.96E-11
3405602 3405587 GPRC5A G protein-coupled receptor, family C, group 5, member A −9.54 skipped 2.14E-15
2598263 2598261 FN1 Fibronectin 1 −9.38 skipped 5.71E-08
3264344 3264326 ACSL5 Acyl-CoA synthetase long-chain family member 5 −9.28 skipped 4.21E-15
3058819 3058759 SEMA3C Semaphorin-3C −9.22 skipped 3.30E-11
3762200 3762198 COL1A1 Collagen, type I, alpha 1 13.64 included 3.86E-14
3013163 3013054 COL1A2 Collagen, type I, alpha 2 9.50 included 4.50E-11
3013162 3013054 COL1A2 Collagen, type I, alpha 2 8.44 included 7.09E-11
3762202 3762198 COL1A1 Collagen, type I, alpha 1 6.87 included 3.35E-13
3762203 3762198 COL1A1 Collagen, type I, alpha 1 6.35 included 4.02E-08
2535909 2535859 CAPN10 Calpain 10 6.30 included 7.07E-09
3351230 3351200 TMPRSS4 Transmembrane protease, serine 4 5.89 included 1.38E-09
3193625 3193482 COL5A1 Collagen, type V, alpha 1 5.81 included 9.30E-12
2405001 2404999 MARCKSL1 MARCKS-like 1 5.74 included 1.10E-11
2535912 2535859 CAPN10 Calpain 10 5.62 included 8.34E-07
Table 3. Top differentially spliced protein-coding genes between PDAC and normal pancreas.
Figure 3. Real-time PCR validation of exon array data. (A) Selection of 8 splicing probe-sets from non-
differentially expressed genes. For these 8 genes/probe-sets, there were no differences in the level of gene 
expression, but significant differences in the level of probe-set expression. (B) RT-PCR results of the 8 probe-
sets. RT-PCR results are represented as scatter dot plots of expression fold change in PDAC compared to normal 
pancreas, with the significance level shown at the top (* < 0.05, ** < 0.01, *** < 0.001). Corresponding exon 
array results are reported in histograms of log2 FIRMA fold change (PDAC/normal) values. The two sets of 
results corresponded well with each other very well.
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normal tissues, with a fold change of 2.03 for ROBO1 and 1.68 for LRP8. Real-time PCR validated the exon array 
results for the selected splicing events in both ROBO1 (Fig. 5A) and LRP8 (Fig. 5B). Of note, while a lower expres-
sion of probe-sets 2683871 and 2413242 was seen by RT-PCR, the values did not reach statistical significance. 
For ROBO1, a higher skipping rate for probe-sets/exons at the 5′ end (represented by probe-set 2683870 and 
2683871), but a higher inclusion rate for probe-sets/exons at the 3′ end (e.g., 2683766) and for some cassette exons 
in the middle (e.g., 2683792) were seen in PDAC compared to normal (Fig. 5A). Similarly for LRP8, probe-sets/
exons at the 5′ end (e.g., probe-set 2413284) and cassette exons close to the 5′ side (represented by 2413242) 
appeared to be skipped, but exons in the middle (e.g., 2413224 and 2413229) and those close to the 3′ end tended 
to be included in PDAC compared to normal (Fig. 5B). Thus, it is likely that different promoters were utilised and 
shorter transcripts become the primary choice in PDAC.
In addition to surface proteins affected by DE and AS being candidate drug targets, the discovery of 
PDAC-associated splice variants might also represent a novel diagnostic opportunity. Using mass spectrometry, 
Menon et al. have detected a number of protein products of gene splice variants in the plasma of a KrasG12D/
Ink4a/Arf mouse model of PDAC20. When these splice isoforms were compared to our AS signatures, 32 com-
mon AS genes were found; interestingly, these genes were highly enriched for focal adhesion (adj. p = 1.24e-03) 
and ECM-receptor interaction (adj. p = 2.49e-03), including TNC, several collagen genes, ZYX, MYLK and FN1. 
These highly conserved AS variant proteins represent an intriguing lead for further validation of their diagnostic 
potential.
Hypersensitive genes. We next tested the behaviour of putative driver genes recently reported by Bailey et 
al.17 regarding differential expression and alternative splicing events. Fifty-six mutated genes were reported using 
the IntoGen software (Q < 0.1, Supplementary Table S4A from ref. 17); of these, four genes showed significant DE 
signatures between PDAC and normal in our dataset (based on the double threshold of adjusted p-value < 1e-04 
and absolute FC > 2), including three upregulated: KRAS, TGFBR1 and CALD1, and one downregulated (FBLN2) 
gene in PDAC. An additional eight DE genes could be identified (using just adjusted p-value < 1e-04), includ-
ing four upregulated (MACF1, TNIK, TP53BP2 and PBRM1), and four downregulated genes: ACVR1B, RBM10, 
BCORL1 and TTC18 in PDAC compared to normal (Supplementary Table S4B).
When the AS patterns were investigated for these 56 genes, seven genes displayed AS signatures. Among 
them, TGFBR2, KDM6A, CALD1 and MYCBP2 all had highly skipped probe-sets, while TGFBR1, MACF1 and 
ITPR3 possessed both highly skipped and included probe-sets in PDAC compared to normal (Supplementary 
Table S4C). Thus, a set of three significantly mutated genes that were significantly mutated and also showed both 
DE and AS was derived, including TGFBR1, CALD1 and MACF1 (Supplementary Fig. S5). Interestingly, both 
alternative first and last exons were significant events for TGFBR1, implying the differential selection of regulatory 
elements in PDAC development for this gene (Supplementary Fig. S5C).
We further expanded our analysis to genes that were significantly targeted by deletions and amplifications, 
revealed by the copy number GISTIC analysis17. A total of 17 out of 21 genes (81.0%) in significantly deleted 
regions that had strong DE signatures were downregulated in PDAC based on our double threshold, demon-
strating good concordance between gene expression and copy number changes, including ARHGDIG, RPL3L, 
Figure 4. Comparison between DE and AS genes. (A) The overlapping patterns between differentially 
expressed (DE) genes and alternatively spliced (AS) genes. (B) The KEGG pathway enrichment for unique DE 
genes (red), unique AS genes (green) and genes with both DE and AS signatures (blue). The –log10 (adjusted p-
values) is shown at the y-axis.
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Figure 5. Analysis of multiple splicing events for ROBO1 and LRP8, and validation with RT-PCR. (A) 
Alternative splicing for ROBO1. (B) Alternative splicing for LRP8. The UCSC transcripts are shown at the top. 
For all quantified core probe-sets, means for probe-set expression and FIRMA values (log2 scaled), and the log2 
FIRMA fold changes (PDAC/normal) were shown underneath UCSC transcripts. The probe-sets chosen for 
RT-PCR validation were shown with the black solid lines, with their positions within the transcripts indicated. 
RT-PCR results for the chosen probe-sets are represented as scatter dot plots of expression fold change in PDAC 
compared to normal pancreas, with the significance level shown at the top (* < 0.05, ** < 0.01, *** < 0.001). 
Corresponding exon array results are also reported in histograms of log2 FIRMA fold change (PDAC/normal) 
values. Both ROBO1 and LRP8 are coding for cell-surface proteins, and both were transcribed in the reverse 
strand.
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SNORA64, RAB26, GOLGA8A/B and MAPK8IP2 (Supplementary Table S4D). The 121 genes within the signif-
icantly amplified regions in PDAC were also significantly differentially expressed, with 74 (61.2%) upregulated 
genes, including ITGA2, VCAN, THBS2, IL7R, LOX and EDIL3 (Supplementary Table S4E).
We then inspected the AS patterns of genes within deleted and amplified regions, and found that 12 deleted 
and 95 amplified genes also displayed strong AS (Supplementary Table S4F and G). Of these, 34 genes additionally 
showed DE signatures, consisting of ABCA3, a deleted and downregulated gene in PDAC, and 33 amplified and 
upregulated genes (including ADAM19, CAST, CD180, CSTB, DOCK2, F2R, MX1, PCDH7, RUNX1, TGFBI and 
VCAN) are listed in Supplementary Table S4H.
The inclusion of the three significantly mutated genes (TGFBR1, CALD1 and MACF1) to the latter 34 genes 
resulted in 37 genes that we refer to as a set of ‘hypersensitive’ genes, as they are frequently targeted by somatic 
mutations, copy number aberrations, differential expression and alternative splicing, indicating their increased 
intrinsic susceptibility to multiple genomic aberrations in PDAC.
Spliceosomal and splicing regulator genes in PDAC. Finally, in order to understand the behaviour 
of the spliceosomal machinery in PDAC, we have assessed the DE and AS of genes involved in splicing. Among 
the 140 spliceosomal genes reported by Zhou et al.21, the expression data for 119 (85%) were investigated in our 
study (Supplementary Table S5A). Of these, 28 (23.5%) genes were significantly differentially expressed (using 
an adjusted p-value threshold of 1e-04) in PDAC, with 22 upregulated genes, the top two being PRPF40A and 
SNRNP27 (Supplementary Table S5A). Interestingly, unsupervised hierarchical clustering of the 119 spliceosomal 
genes showed clear separation between normal and PDAC samples as illustrated in Fig. 6A. To detect a potential 
influence of age on PDAC clustering, we investigated the association between PDAC sample clustering of spli-
ceosomal genes and patient age, but found no significant difference in age between the two groups of patients 
(Wilcoxon test, p = 0.90). This was also the case when we explored the association between age and patients’ 
clustering based on significant AS probe-sets (Fig. 2A), Wilcoxon test, p = 0.20.
Previously, Carrigan et al. analysed AS in PDAC cell lines and demonstrated that 28 of 92 (~30%) spliceo-
somal genes had significantly decreased expression in pancreatic cancer compared with normal pancreas11; in 
our study, expression profiles for 18 of these 28 genes were identified and only three of them (SART1, CIRBP 
and HTATSF1) were significantly downregulated in PDAC (adjusted p < 0.05), while nine (DNAJC8, DHX9, 
DHX8, SLU7, RSRC2, MBNL2, NCBP2, PRPF4B and MBNL3) were significantly upregulated (adjusted p < 0.05) 
(Supplementary Fig. S6). This difference is likely due to the different analytical platforms and sample types uti-
lised in the two studies. When the selection of spliceosomal genes was expanded to all 238 splicing regulators 
based on the Ensembl annotation (Supplementary Table S5B), 73/238 (30.7%) of these genes were found to be 
differentially expressed (adjusted p-value < 1e-04), with 39 upregulated and 34 downregualted genes in PDAC 
relative to normal. The top upregulated genes (FC > 2) included PRPF40A, SNRNP27, LGALS3, and ADAR, and 
Figure 6. Heatmap showing the expression profiles of 119 (A) and 238 (B) spliceosomal genes, with the 
upregulated genes shown in red and downregulated in green. PDAC samples were indicated with the brown bar, 
while normal samples were indicated with the blue bar.
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the top downregulated genes (FC < 0.5) included APOBEC2, CELF3, ADARB2 and CSDC2 (Supplementary 
Table S5B). Unsupervised clustering based on all 238 spliceosomal genes was again able to differentiate PDAC 
from the healthy pancreas (Fig. 6B).
Interestingly, 12 spliceosomal genes: AQR, C19orf43, DHX16, PPM1G, PUF60, SNRPD3, SRSF1, SRSF4, 
TCERG1, U2AF2, USP39 and WTAP also showed the evidence of AS - all had skipped exon signatures in PDAC 
(Supplementary Table S2). Thus, genes in spliceosomal machinery are themselves regulated by both DE and to a 
lesser extent by AS. This could potentially explain and be one of the reasons for a compromised splicing fidelity in 
cancer. Of note, we did not find any association between the aberrations of spliceosomal machinery and patients’ 
age.
Discussion
Here, we provide the first comprehensive tissue-based AS landscape of PDAC, with the report of a number of 
newly identified AS events. We show that the most common alterations in the protein-coding AS genes in PDAC 
are skipped exon and alternative 1st exon, followed by intron retention. Exon skipping was previously highlighted 
as being the most common AS form involved in shaping eukaryotic evolution22, and we show here that the same 
mechanism is also utilised in PDAC development. In contrast, intron retention, a rare event in normal eukaryotic 
tissues (most commonly seen in plants, fungi and protozoa)1 seemed to be also hijacked in PDAC evolution. This 
inclusion of intronic sequences within the mRNA (sometimes referred to as the phenomenon of exonization) 
has been reported in cancer23, suggesting that aberrant AS is not merely a side effect of cancer, but a bona fide 
regulator of cancer development22.
In addition to our validation, a number of genes affected by AS described here have already been reported, 
providing an independent validation of our data. A total of 121 genes (8.9%) found to have AS signatures in our 
PDAC cohort were also found to have skipped exons across different tissues4 (Supplementary Table S6). The AS 
of CALD1, COL6A3, FN1, MAST2, LGR5 and ITGB4 were previously validated in colon cancer using RT-PCR24, 
while CLSTN1, AUP1, CTNND1, CALD1 and COL6A3 were shown to exhibit tumour-specific splice variants in 
colon, bladder and prostate cancers8. ADAM12, DKK3, GSN, TNFSF11, CDH3, CXCL5, HCK, ITGA5 and VEGFC 
have also been shown to possess known or novel splice variants in lung cancer25. The BIRC5 (survivin) gene and 
its spliced isoforms have been shown to be associated with prostate cancer cell proliferation and aggressive phe-
notypes26; and tumour-associated splice variants of MACF1, ITGB3, TLE3, SHC1, ETS1 and BCAS1 have been 
reported in lung, prostate, breast cancer and glioblastoma27–32.
In PDAC, AS in PSMD2, PTPN18, SUPT16H, CUL4A, NIN, SLK, and ABCC3 were also reported previously11, 
and increased AS of the KLF6 tumour suppressor gene was shown to correlate with prognosis and tumour 
grade33. Interestingly, in our data, four other members of the Krüppel-like family, KLF5, KLF7, KLF12 and KLF16, 
also showed significant AS events (Supplementary Table S2A). The AS in human tissue factor (TF or F3) was 
shown to promote tumour growth in an orthotopic pancreatic cancer model34, 35, and our data also show a highly 
skipped event for this gene (within the first exon) in PDAC (probe-set: 2423935; FIRMA log2FC = −4.69, adj. 
p = 1.99e-08).
Overall, collagen genes showed the highest versatility in AS in PDAC; interestingly, a switch in alternate pro-
moters in collagen IX during fracture healing36, and a dynamic process of tumour-specific AS in several exons of 
COL6A3 were previously reported37. While in evolutionary terms increased splicing presents novel opportuni-
ties for expansion of gene families, its functional implications are far-reaching, particularly in PDAC, where the 
abundant stroma, predominantly composed of collagens, is a characteristic and pronounced feature. It is highly 
plausible that alternatively spliced collagen genes play a critical role in intense stromal remodelling with impor-
tant repercussions to mechanical and stiffness properties, shown recently to be implicated in progression and 
invasive properties of PDAC38.
Of note, while our samples were pre-selected to predominantly comprise tumour cells, it is possible that a 
large number of AS signatures seen here in collagen and other ECM genes are derived from the desmoplastic 
stromal compartment still present in our samples. Therefore, future studies that involve the microdissection and 
AS profiling of both tumour and stromal cells will further enrich our understanding of this phenomenon, and 
inform on tumour and stroma specific AS events in PDAC. Furthermore, to compare the AS/DE profile of chronic 
pancreatitis to that of normal and/or tumour tissues would also be an important further step in understanding the 
degree to which differences described here are tumour-specific.
Around a third of the significant genes in our study were shown to be affected by both DE and AS (Fig. 4), and 
they were particularly enriched for ECM-receptor interaction and focal adhesion pathways as well as complement 
and coagulation cascades. Of these genes, 135 encode cell surface proteins. Although it still remains to be fully 
established if these events are PDAC-specific, such surface proteins might represent an as yet untapped source of 
both potential imaging tools or drugable targets. Furthermore, the discovery of PDAC-associated splice variants 
in body fluids might present a novel diagnostic opportunity, as at least 32 AS gene products were found as cir-
culating proteins in mouse plasma20. These represent a rich pool of non-invasive diagnostic candidates that now 
need to be explored and validated directly in human biofluids.
Interestingly, we describe here a group of hypersensitive genes, which showed predilection to be affected by 
mutations, copy number aberrations, DE and AS signatures. While the detailed mechanistic annotation for such 
a multidimensional regulation of this set of genes remains to be further established, their functionality in the 
ECM-receptor interactions, focal adhesion, collagen fibril organisation and actin cytoskeleton provides a versa-
tility of options in communication networks between cancer cells and their ever-changing microenvironment.
Finally, we also looked at the spliceosomal machinery itself. A deregulation of around a third of genes belong-
ing to this dynamic ribonucleoprotein complex was found, with upregulation being more prevalent than down-
regulation; this has also been established for the majority of other cancers. Based on the percentage of upregulated 
vs. downregulated splicing factor genes, PDAC appeared to be more similar to renal cell carcinoma and lung 
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adenocarcinoma than to prostate, colorectal and breast cancers5. Of note, the spliceosomal signature itself was 
sufficient to clearly separate the normal and cancer specimens, suggesting its cancer-specificity; curiously, we also 
show that several spliceosomal genes can undergo alternative splicing themselves.
It was previously shown that spliced isoforms follow the principle of parsimony and adopt the simplest struc-
tural folds, with the most pronounced changes seen in the exposed surface of the affected proteins39. Integration 
of our data with the RNA-Seq data and development and refinement of the computational prediction methods 
to inform on the resultant protein sequence and corresponding 3D structural models on a global scale is now 
needed to gain full benefit from the available AS data.
In summary, we provide the most comprehensive landscape of AS events in PDAC to date, with underlying 
changes in the spliceosome and its regulators. We also report a group of alternatively spliced genes that encode 
surface and circulating proteins. These represent novel candidates of translational relevance as potential diagnos-
tic and therapeutic targets in pancreatic adenocarcinoma.
Materials and Methods
Samples and RNA isolation. A total of 43 freshly-frozen pancreatic samples (37 PDAC, four histologically 
normal samples adjacent to cancer and two normal donor tissue samples) were analysed in this study. Samples 
were obtained from the Department of Pathology, Verona, Italy, after informed consent with full ethical approval 
from the Institutional Review Boards of The University of Verona. The experiment and methods were conducted 
in accordance with the Declaration of Helsinki. The demographic and clinical information of the patients and 
samples are summarised in Table 1. Of note, the samples have been selected based on tumour cellularity, so over 
80% of PDAC specimens had >60% cancer cell content.
Total RNA was isolated using TRIzol (Invitrogen); 1.5 μg of total RNA was further processed (depleted of 
ribosomal RNA and labelled) according to supplied protocols (Affymetrix, Santa Clara, CA, USA).
Affymetrix Exon array expression analysis. Affymetrix GeneChip® Human Exon 1.0 ST Arrays, com-
prising ~1.4 million probe-sets consisting of over 5 million individual probes and >300,000 transcript clusters 
(group of probe-sets targeting individual exons in genes and noncoding transcripts) were used for gene-level 
expression profiling and AS analysis. Labelling using Affymetrix GeneChip Whole Transcript (WT) ST Labeling 
Assay and subsequent hybridization were performed according to the manufacturer’s instructions. After scan-
ning, CEL files were checked for quality and analysed following the pipeline described in Rodrigo-Domingo et 
al.40. Exon array data files have been submitted to Gene Expression Omnibus (GEO) under the accession number 
of GSE63158, a SuperSeries consisting of the gene-level data GSE56560 and the exon-level data GSE63111.
Within the pipeline, the “aroma. affymetrix” R package41 was used for data preprocessing, normalisation and 
summarisation to produce transcript, probe-set and probe-level intensities. Here, only the “core” probe-sets, sup-
ported by the most reliable evidence from RefSeq and full-length mRNA GenBank records containing complete 
coding DNA sequence (CDS) information and transcript clusters were used. This was followed by intensity fil-
tering across samples as recommended by the Affymetrix White Paper10. Data obtained from one replicate of 
the two donor samples were of low quality and were subsequently removed. Using the limma R package42, tran-
script cluster expression intensities were further analysed to identify differentially expressed (DE) transcripts 
between PDAC and control groups. The raw p-values were adjusted using the Benjamini-Hochberg (BH) model43. 
Differentially expressed transcript clusters were identified using a double threshold of adjusted p-value < 1e-04 
and absolute fold change (FC) > 2. The transcript clusters were further matched to Ensembl genes and gene 
symbols.
Alternative splicing (AS) analysis. Differential alternative splicing events were detected using FIRMA 
(Finding Isoforms using Robust Multichip Analysis)44. FIRMA scores for all filtered probe-sets were calculated 
using “aroma. affymetrix”. After log2 transformation, the differential splicing analysis was conducted using limma. 
Alternatively spliced probe-sets were identified using a double threshold of adjusted p-value < 1e-06 and absolute 
log2 FC > 2. The ANalysis Of Splice VAriation (ANOSVA) method45 was also used as an additional filter with an 
adjusted p-value < 1e-06 at both the probe and probe-set levels. Only protein-coding genes were finally selected 
according to the Ensembl gene annotation. Identified AS events in PDAC were categorised into common patterns 
of alternatively spliced exonic regions according to the Ensembl alternative splicing event set4, 46, i.e. alternative 
5′ and 3′ sites, alternative first and last exon, skipped and consecutive exon, intron retention and isoform and 
mutually exclusive exons.
Gene set enrichment tests. The gene set enrichment tests were performed using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID)12 to inspect overrepresented Gene Ontology (GO) 
Biological Process terms and KEGG pathways. The p-values were adjusted using the BH model. The functional 
and pathway analyses were also conducted using Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, www.
ingenuity.com). To identify surface protein coding genes, the GO Cellular Component terms for genes were 
explored using DAVID to determine those coding for plasma membrane proteins.
Real-time PCR validation. First strand cDNA was prepared from 1 µg of total human pancreatic RNA 
using Quantitect Reverse Transcription kit (Qiagen, Crawley, UK). Real-time PCR was performed on a 7500 
Real Time PCR System (Applied Biosystems, Warrington, UK) using SYBR Green dye (Qiagen) according to the 
manufacturer’s instruction. Specific primers were designed and evaluated for amplification efficiency with the use 
of Universal Human Reference RNA (Agilent technologies, Stockport, UK) (Supplementary Table S7). To confirm 
the exon array data, relative changes of expression were shown for each target after normalization to the reference 
genes HPRT1, RPLP0 and S16, according to the formula: 2ΔΔCt47. In addition to samples used for Affymetrix 
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experiments, eight more PDAC and four more pancreatic normal tissues were used; in total, the validation was 
performed on 20 PDAC and six normal samples.
Molecular subtype analysis. In addition to our exon array dataset, an analogous dataset from Zhang et 
al.15, was also used for clinical inferences. The two data sets (gene expression and clinical follow-up) were com-
piled, processed and merged as previously reported48. To identify PDAC molecular subtypes using the Collisson 
gene signature14, non-negative matrix factorisation (NMF) consensus clustering49 was employed to identify stable 
sample clusters based on normalised or z-score standardised expression values for each dataset. The R pack-
age ‘ConsensusClusterPlus”50 was also used to verify sample clustering. After sample clustering and grouping, 
Kaplan-Meier (KM) analysis and Log Rank test as well as Cox proportional hazards model were undertaken for 
survival analyses examining the impacts of grouping on overall survival using the R ‘survival’ package (https://
cran.r-project.org/web/packages/survival/).
References
 1. Keren, H., Lev-Maor, G. & Ast, G. Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 
11, 345–355 (2010).
 2. Skotheim, R. I. & Nees, M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 39, 1432–1449 
(2007).
 3. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome 
by high-throughput sequencing. Nat Genet 40, 1413–1415 (2008).
 4. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008).
 5. Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A. & Skotheim, R. I. Aberrant RNA splicing in cancer; expression changes and 
driver mutations of splicing factor genes. Oncogene 35, 2413–2427 (2016).
 6. Pagliarini, V., Naro, C. & Sette, C. Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation. Biomed Res Int 
2015, 543067 (2015).
 7. Ladomery, M. Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol 2013, 463786 (2013).
 8. Thorsen, K. et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Molecular & cellular 
proteomics: MCP 7, 1214–1224 (2008).
 9. Wang, Z. et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. 
Cancer Res 63, 655–657 (2003).
 10. Affymetrix. Alternative transcript analysis methods for exon arrays http://www.affymetrix.com/support/technical/whitepapers/
exon_alt_transcript_analysis_whitepaper.pdf. The White Paper (2005).
 11. Carrigan, P. E., Bingham, J. L., Srinvasan, S., Brentnall, T. A. & Miller, L. J. Characterization of alternative spliceoforms and the RNA 
splicing machinery in pancreatic cancer. Pancreas 40, 281–288 (2011).
 12. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics 
resources. Nature protocols 4, 44–57 (2009).
 13. Dayem Ullah, A. Z. et al. The pancreatic expression database: recent extensions and updates. Nucleic Acids Res 42 (2014).
 14. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature medicine 17, 
500–503 (2011).
 15. Zhang, G. et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic 
ductal adenocarcinoma. PLoS One 7, e31507 (2012).
 16. Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal 
adenocarcinoma. Nat Genet 47, 1168–1178 (2015).
 17. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
 18. Lapuk, A. et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 8, 961–974 
(2010).
 19. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
 20. Menon, R. et al. Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic 
cancer. Cancer Res 69, 300–309 (2009).
 21. Zhou, Z., Licklider, L. J., Gygi, S. P. & Reed, R. Comprehensive proteomic analysis of the human spliceosome. Nature 419, 182–185 
(2002).
 22. Kim, E., Goren, A. & Ast, G. Insights into the connection between cancer and alternative splicing. Trends Genet 24, 7–10 (2008).
 23. Dvinge, H. & Bradley, R. K. Widespread intron retention diversifies most cancer transcriptomes. Genome Med 7, 45 (2015).
 24. Gardina, P. J. et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC 
genomics 7, 325 (2006).
 25. Xi, L. et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. 
Nucleic acids research 36, 6535–6547 (2008).
 26. Koike, H., Sekine, Y., Kamiya, M., Nakazato, H. & Suzuki, K. Gene expression of survivin and its spliced isoforms associated with 
proliferation and aggressive phenotypes of prostate cancer. Urology 72, 1229–1233 (2008).
 27. Jin, R., Trikha, M., Cai, Y., Grignon, D. & Honn, K. V. A naturally occurring truncated beta3 integrin in tumor cells: native anti-
integrin involved in tumor cell motility. Cancer biology & therapy 6, 1559–1568 (2007).
 28. Laitem, C. et al. Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular 
localization of Ets-1 p51. Oncogene 28, 2087–2099 (2009).
 29. Misquitta-Ali, C. M. et al. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. 
Molecular and cellular biology 31, 138–150 (2011).
 30. Nakaya, H. I. et al. Splice variants of TLE family genes and up-regulation of a TLE3 isoform in prostate tumors. Biochemical and 
biophysical research communications 364, 918–923 (2007).
 31. Venables, J. P. et al. Identification of alternative splicing markers for breast cancer. Cancer Res 68, 9525–9531 (2008).
 32. Cheung, H. C. et al. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC genomics 9, 
216 (2008).
 33. Hartel, M. et al. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in 
patients with pancreatic cancer. European journal of cancer 44, 1895–1903 (2008).
 34. Hobbs, J. E. et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor 
model. Thrombosis research 120(Suppl 2), S13–21 (2007).
 35. Unruh, D. et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal 
adenocarcinoma. Int J Cancer 134, 9–20 (2014).
 36. Hiltunen, A. et al. Expression of type VI, IX and XI collagen genes and alternative splicing of type II collagen transcripts in fracture 
callus tissue in mice. FEBS Lett 364, 171–174 (1995).
www.nature.com/scientificreports/
13Scientific RepoRts | 7: 2980  | DOI:10.1038/s41598-017-03354-z
 37. Arafat, H. et al. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery 150, 306–315 
(2011).
 38. Laklai, H. et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor 
progression. Nat Med 22, 497–505 (2016).
 39. Wang, P., Yan, B., Guo, J. T., Hicks, C. & Xu, Y. Structural genomics analysis of alternative splicing and application to isoform 
structure modeling. Proc Natl Acad Sci USA 102, 18920–18925 (2005).
 40. Rodrigo-Domingo, M. et al. Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. Briefings 
in bioinformatics (2013).
 41. Bengtsson, H., Simpson, K., Bullard, J. & Hansen, K. aroma.affymetrix: A generic framework in R for analyzing small to very large 
Affymetrix data sets in bounded memory. Tech Report #745, Department of Statistics University of California, Berkeley (2008).
 42. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical 
applications in genetics and molecular biology 3, Article3 (2004).
 43. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal 
of the Royal Statistical Society Series B-Methodological 57, 289–300 (1995).
 44. Purdom, E. et al. FIRMA: a method for detection of alternative splicing from exon array data. Bioinformatics 24, 1707–1714 (2008).
 45. Cline, M. S. et al. ANOSVA: a statistical method for detecting splice variation from expression data. Bioinformatics 21(Suppl 1), 
i107–115 (2005).
 46. Koscielny, G. et al. ASTD: The Alternative Splicing and Transcript Diversity database. Genomics 93, 213–220 (2009).
 47. Dumartin, L. et al. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of 
cathepsins B and D. Cancer Res 71, 7091–7102 (2011).
 48. Haider, S. et al. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med 6, 105 
(2014).
 49. Brunet, J. P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. Proc 
Natl Acad Sci USA 101, 4164–4169 (2004).
 50. Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. 
Bioinformatics 26, 1572–1573 (2010).
Acknowledgements
The study was funded by the MolDiagPaCa European Union Framework Programme and CR-UK Programme 
grant A12008 from CR-UK (C. Chelala, T. Crnogorac-Jurcevic, and N.R. Lemoine). Italian Cancer Genome 
Project – Ministry of University [FIRB RBAP10AHJB]; Associazione Italiana Ricerca Cancro [grant number: 
12182]; FP7 European Community Grant Cam-Pac [no: 602783]; Italian Ministry of Health [FIMP- 
CUP_J33G13000210001]. The funders were not involved in the design of the study, collection, analysis, and 
interpretation of data and in writing of the manuscript. We thank Tracy Chaplin-Perkins for help with running 
the Affymetrix experiments.
Author Contributions
Study concept and design: C.C., A.S., N.R.L., T.C.J.; Acquisition of data: P.U., L.D., N.A.A., T.P.R.; Analysis and 
interpretation of data: J.W., L.D., A.S., A.M., C.C., T.C.J.; Drafting of the manuscript: J.W., L.D., T.C.J.; Critical 
revision of the manuscript for important intellectual content: J.W., C.C., T.C.J.; Material and clinical data support: 
R.T.L., R.S., A.S.; study supervision: C.C., T.C.J. All authors have reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-03354-z
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
